Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Talniflumate (Genaera).

Darryl Knight1

  • 1Experimental Biology Division, Asthma & Allergy Research Institute, Department of Medicine, Sir Charles Gairdner Hospital, University of Western Australia, Hospital Avenue, Nedlands, WA 6009, Australia. dknight@cyllene.uwa.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.

Respirology (Carlton, Vic.)·2025
Same author

Design, delivery, and evaluation of a knowledge translation intervention for multi-stakeholders.

Implementation science communications·2023
Same author

TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells.

International journal of pharmaceutics·2022
Same author

Pharmacological HIF-1 stabilization promotes intestinal epithelial healing through regulation of α-integrin expression and function.

American journal of physiology. Gastrointestinal and liver physiology·2021
Same author

TLR2-mediated innate immune priming boosts lung anti-viral immunity.

The European respiratory journal·2020
Same author

Long-chain fatty acids are bad in IPF, or are they?

Respirology (Carlton, Vic.)·2020

Talniflumate is an anti-inflammatory drug being developed as a mucoregulator. It is being investigated for cystic fibrosis, chronic obstructive pulmonary disease, and asthma.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Talniflumate, an anti-inflammatory agent, was initially developed by Laboratorios Bago.
  • Genaera is currently developing talniflumate.

Purpose of the Study:

  • To evaluate talniflumate as a mucoregulator for respiratory diseases.
  • To assess its efficacy in treating cystic fibrosis, COPD, and asthma.

Main Methods:

  • Phase I clinical trials of talniflumate have been completed.
  • Phase II clinical trials are currently in progress in Ireland.

Main Results:

  • Phase I trials were completed by August 2001.
  • Ongoing Phase II trials are evaluating talniflumate for cystic fibrosis treatment.

Related Experiment Videos

Conclusions:

  • Talniflumate shows potential as a mucoregulator for various respiratory conditions.
  • Further clinical trials are necessary to confirm its therapeutic benefits.